These are secondary-prevention patients (aged >=55 y with prior coronary/peripheral/cerebrovascular disease or complicated diabetes) on cardiovascular medications; qualitative FFQ, models adjusted for BMI, medication, trial allocation and dietary covariates. The null replicates PURE’s neutral finding in a higher-risk population.